Meeting
2019 ASCO Annual Meeting
A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (NCT03528642).
Authors
Sani Haider Kizilbash
Mayo Clinic, Rochester, MN
Sani Haider Kizilbash , Samuel McBrayer , John Port , Joel M. Reid , Ian Lanza , Jacob B Allred , Arnab Chakravarti , Charles Kunos , Alex A. Adjei
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT03528642
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS2075)
DOI
10.1200/JCO.2019.37.15_suppl.TPS2075
Abstract #
TPS2075
Poster Bd #
262a
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase I trial of dimethyl fumarate, temozolomide, and radiation therapy in glioblastoma multiforme.
First Author: Danielle A. Shafer
Poster
2013 ASCO Annual Meeting
Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma or progressive secondary brain tumor.
First Author: James D. Peyton
Poster
2020 ASCO Virtual Scientific Program
Long-term analysis of the WHO-defined molecular subgroups of high-risk grade II gliomas treated with radiation and temozolomide on NRG Oncology/RTOG 0424.
First Author: Erica Hlavin Bell
Poster
2019 ASCO Annual Meeting
Phase I study of procaspase activating compound -1 (PAC-1) in combination with temozolomide (TMZ) for the treatment of recurrent malignant glioma.
First Author: Martin Kelly Nicholas